Current screening modalities for prostate cancer rely on serologic testing for PSA and transrectal biopsy; however, many prostate cancers behave indolently.Because aggressively growing tumors depend o
Comparison of the PhaHV-1 LAMP testing of rapidly processed swabs to the PhaHV-1 reference qPCR testing of DNA extracted from the same swab suspensions.
